-
-
-
-
-
-
-
Novartis's (NVS) Kisqali Cut Risk Of Tumors Returning By 25%
-
-
-
-
-
-
-
PDS Biotechnology (PDSB) Announces Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with KEYTRUDA for Head and Neck Cancer Patients
-
-
-
-
-
-
-
Integra LifeSciences (IART) initiates voluntary global recall of all products manufactured at Boston facility
-
-
-
-
-
-
-
Oculis (OCS) Reports Positive Top Line Results from DIAMOND Stage 1 Phase 3 Trial
-
-
-
-
-
-
-
Roivant(ROIV) Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA Cream, 1%
-
-
-
-
-
-
-
ARS Pharmaceuticals (SPRY) Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on neffy® for the Treatment of Type I Allergic Reactions Including Anaphylaxis
-
-
-
-
-
-
-
Eli Lilly (LLY) rises 9% as its Alzheimer's drug slows diseases progression by 35%
-
5,184 total articles have been posted to this category.
Sign-up to StreetInsider.com Premium
to see all today's market moving Hot FDA News reports.